(Full agenda coming soon)
The following presenters and topics are confirmed for PANAO 2025. Stay tuned to this page for additions and a full agenda soon.
Science-driven early phase clinical trials to dissect molecular mechanisms of drug sensitivity and resistance
Lillian Siu, MD, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Develop T cell receptor (TCR)-T cell therapy that targets HLA-class I and class II natural epitope
Lei Zheng, MD, PhD, UT Health Mays Cancer Center, San Antonio, Texas
Moving the Needle in Acute Myeloid Leukemia
Ronan Swords, MD, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
The Advances in Drug Development/Treatment in Mantle Cell Lymphoma
Preetesh Jain, MD, MD Anderson Cancer Center, Houston, Texas
Identifying therapeutic targets by computational analysis of clinical molecular data
Ritu Pandey, PhD, University of Arizona Cancer Center, Tucson, Arizona
Evolving Cellular Therapy Landscape in Hematologic Malignancies and Solid Tumors
Muhammad Bilal Abid, MD, UT Health Science Center Houston, Houston, Texas
Advances in Head and Neck cancers
Dr. Devi Meyyappan, MD, UT Health Science Center San Antonio, San Antonio, Texas
Delaying resistance to VEGF TKI in metastatic Renal Cell Carcinoma
Saby George, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York
Novel ADCs targeting the immune checkpoint
Daruka Mahadevan, MD, PhD, UT Health Science Center San Antonio, San Antonio, Texas
Polyploid Giant Cancer Cells: Towards a Unified understanding of Therapeutic Resistance and Embryogenesis.
Jingsong Liu, MD, PhD, MD Anderson Cancer Center, Houston, Texas
Developing anti-cancer therapeutics that activate macrophage-mediated phagocytosis.
Ming Wang, PhD, MBA, Phane Therapeutics, San Diego, California
Targeting MTAP loss – synthetic lethality opportunity
Dr. Jordi Rodon, MD Anderson Cancer Center, Houston, Texas
7979 Wurzbach Road
San Antonio, Texas
P: (210) 450 1550
Email: panao@uthscsa.edu